See more : FDK Corporation (6955.T) Income Statement Analysis – Financial Results
Complete financial analysis of ProMIS Neurosciences, Inc. (PMN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of ProMIS Neurosciences, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Lai Si Enterprise Holding Limited (2266.HK) Income Statement Analysis – Financial Results
- Central Plains Bancshares, Inc. Common Stock (CPBI) Income Statement Analysis – Financial Results
- Henan Ancai Hi-Tech Co.,Ltd (600207.SS) Income Statement Analysis – Financial Results
- CombinedX AB (publ) (CX.ST) Income Statement Analysis – Financial Results
- Tianli International Holdings Limited (1773.HK) Income Statement Analysis – Financial Results
ProMIS Neurosciences, Inc. (PMN)
About ProMIS Neurosciences, Inc.
ProMIS Neurosciences, Inc. discovers and develops precision medicine solutions for the treatment of neurodegenerative diseases, primarily Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA) in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates include PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a superoxide dismustase 1 and TAR-DNA binding protein 43 in ALS, as well as alpha synuclein in Parkinson's disease and Lewy body dementia; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils in MSA. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 8.14K | 1.40K | 920.18 | 348.74 | 7.87K | 2.00K | 14.37K | 134.18K | 48.67K | 91.09K | 1.23M | 176.16K | 193.63K | 464.02K | 219.92K | 31.31K |
| Cost of Revenue | 10.44M | 21.78M | 5.85M | 3.18M | 4.74M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -10.44M | -21.78M | -5.84M | -3.18M | -4.73M | 348.74 | 7.87K | 2.00K | 14.37K | 134.18K | 48.67K | 91.09K | 1.23M | 176.16K | 193.63K | 464.02K | 219.92K | 31.31K |
| Gross Profit Ratio | 0.00% | 0.00% | -71,796.88% | -227,041.82% | -514,509.20% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Research & Development | 7.88M | 16.09M | 4.95M | 2.50M | 3.63M | 5.44M | 3.15M | 1.39M | 763.96K | 1.27M | 1.77M | 2.04M | 3.25M | 3.62M | 3.27M | 6.06M | 2.95M | 944.20K |
| General & Administrative | 7.39M | 7.29M | 3.31M | 1.95M | 2.04M | 2.02M | 1.64M | 1.17M | 682.26K | 898.06K | 476.13K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | -1.01M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 6.38M | 7.29M | 3.31M | 1.95M | 2.04M | 2.02M | 1.64M | 1.17M | 682.26K | 898.06K | 476.13K | 536.21K | 1.20M | 1.17M | 824.00K | 1.22M | 885.47K | 351.62K |
| Other Expenses | -5.81M | 115.53K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 75.96K | 212.41K | 154.43K | 178.36K | 163.50K | 51.04K | 9.64K |
| Operating Expenses | 8.45M | 23.38M | 8.26M | 4.44M | 5.66M | 7.46M | 4.79M | 2.56M | 1.45M | 2.17M | 2.24M | 2.65M | 4.66M | 4.94M | 4.27M | 7.45M | 3.89M | 1.31M |
| Cost & Expenses | 18.90M | 23.38M | 8.26M | 4.44M | 5.66M | 7.46M | 4.79M | 2.56M | 1.45M | 2.17M | 2.24M | 2.65M | 4.66M | 4.94M | 4.27M | 7.45M | 3.89M | 1.31M |
| Interest Income | 0.00 | 0.00 | 4.73K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.29K | 13.53K | 46.99K | 131.51K | 193.63K | 193.63K | 0.00 | 0.00 |
| Interest Expense | -201.39K | 282.06K | 415.03K | 0.00 | 0.00 | 0.00 | 5.65K | 15.89K | 23.98K | 0.00 | 2.29K | 13.53K | 46.99K | 131.51K | 193.63K | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 28.04K | 15.19K | 45.83K | 12.33K | 6.55K | 4.90K | 5.31K | 4.96K | 5.50K | 14.78K | 49.45K | 75.96K | 212.41K | 154.43K | 178.36K | 163.50K | 51.04K | 9.64K |
| EBITDA | -17.81M | -29.88M | -9.33M | -4.43M | -5.66M | -7.46M | -4.78M | -2.55M | -1.51M | -2.88M | -2.02M | -2.15M | -2.49M | -3.13M | -4.61M | -3.90M | -6.82M | -3.62M |
| EBITDA Ratio | 0.00% | 0.00% | -100,802.23% | -315,985.67% | -614,617.22% | -2,139,026.95% | -60,699.29% | -127,551.65% | -9,929.36% | -1,508.22% | -4,408.57% | -2,730.51% | -261.17% | -2,617.02% | -2,013.48% | -1,470.16% | -1,645.59% | -2,724.12% |
| Operating Income | -18.90M | -23.38M | -8.25M | -4.44M | -5.66M | -7.46M | -4.78M | -2.56M | -1.51M | -2.04M | -2.19M | -2.56M | -3.43M | -4.76M | -4.08M | -6.99M | -3.67M | -1.69M |
| Operating Income Ratio | 0.00% | 0.00% | -101,363.57% | -316,865.81% | -615,329.37% | -2,140,431.58% | -60,766.72% | -127,799.59% | -10,519.49% | -1,519.23% | -4,510.18% | -2,813.90% | -278.43% | -2,704.69% | -2,105.59% | -1,505.39% | -1,668.80% | -5,382.95% |
| Total Other Income/Expenses | 1.39M | 7.20M | -1.50M | 1.22M | 0.00 | 0.00 | -5.65K | -11.82K | -17.28K | -853.75K | 0.00 | 40.59K | 13.50 | 3.34M | 0.00 | 4.08M | 3.32M | 1.98M |
| Income Before Tax | -17.51M | -18.06M | -9.24M | -4.44M | -5.66M | -7.46M | -4.79M | -2.57M | -1.53M | -2.04M | -2.19M | -2.55M | -3.43M | -4.76M | -4.08M | -6.99M | -3.67M | -1.69M |
| Income Before Tax Ratio | 0.00% | 0.00% | -113,562.83% | -316,865.81% | -615,329.37% | -2,140,431.58% | -60,838.50% | -128,390.00% | -10,639.79% | -1,519.23% | -4,505.49% | -2,799.05% | -278.43% | -2,704.69% | -2,105.59% | -1,505.39% | -1,668.80% | -5,388.21% |
| Income Tax Expense | -167.90K | -5.32M | 415.03K | 0.14 | 0.00 | -156.24K | 5.65K | 11.82K | 17.28K | 0.91 | -2.29K | 2.55M | 3.43M | 4.76M | 4.08M | 6.99M | 3.67M | 1.69M |
| Net Income | -17.51M | -12.74M | -9.66M | -4.44M | -5.66M | -7.46M | -4.79M | -2.57M | -1.53M | -2.04M | -2.19M | -2.55M | -3.43M | -4.76M | -4.08M | -6.99M | -3.67M | -1.69M |
| Net Income Ratio | 0.00% | 0.00% | -118,662.24% | -316,865.81% | -615,329.37% | -2,140,431.58% | -60,838.50% | -128,390.00% | -10,639.79% | -1,519.23% | -4,505.49% | -2,799.05% | -278.43% | -2,704.69% | -2,105.59% | -1,505.39% | -1,668.80% | -5,388.21% |
| EPS | -1.42 | -1.70 | -1.67 | -0.93 | -1.31 | -1.87 | -1.40 | -0.91 | -0.85 | -2.02 | -2.32 | -2.99 | -4.21 | -5.99 | -5.83 | -10.15 | -6.93 | -5.24 |
| EPS Diluted | -1.42 | -1.70 | -1.67 | -0.93 | -1.31 | -1.87 | -1.40 | -0.91 | -0.85 | -2.02 | -2.32 | -2.99 | -4.21 | -5.99 | -5.83 | -10.15 | -6.93 | -5.24 |
| Weighted Avg Shares Out | 12.29M | 7.50M | 5.79M | 4.76M | 4.33M | 3.99M | 3.43M | 2.83M | 1.80M | 1.01M | 945.75K | 854.13K | 813.26K | 795.18K | 699.76K | 688.30K | 529.29K | 321.77K |
| Weighted Avg Shares Out (Dil) | 12.29M | 7.50M | 5.79M | 4.76M | 4.33M | 3.99M | 3.43M | 2.83M | 1.80M | 1.01M | 945.75K | 854.13K | 813.26K | 795.18K | 699.76K | 688.30K | 529.29K | 321.77K |
Promis Neurosciences to Present at the Oppenheimer 33rd Annual Healthcare Conference
Source: https://incomestatements.info
Category: Stock Reports